trending Market Intelligence /marketintelligence/en/news-insights/trending/bgsP9KKZbtSx_74sMnnexA2 content esgSubNav
In This List

AstraZeneca's Farxiga gets US FDA fast-track tag for heart failure

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AstraZeneca's Farxiga gets US FDA fast-track tag for heart failure

AstraZeneca PLC's Farxiga received the U.S. Food and Drug Administration's fast-track status to reduce the risk of two types of heart failure.

The medicine, which is also known as dapagliflozin, is being developed to reduce the risk of cardiovascular death in patients with either reduced ejection fraction, or HFrEF, or preserved ejection fraction, or HFpEF.

SNL Image

Heart failure affects about 64 million people worldwide and at least half of them have a reduced ejection fraction.

The fast-track designation is based on two late-stage trials, dubbed DAPA-HF and DELIVER, conducted to test Farxiga in HFrEF patients and HFpEF patients respectively.

Previously, the Cambridge, U.K.-based company's medicine received fast-track status by the U.S. FDA to help delay the progression of renal failure.